Aptima® HBV Quant Assay

Back to Products

Aptima® HBV Quant Assay

Deliver trusted results with dual targets across a wide linear range and all major HBV genotypes.

More Information

Download the Brochure

Overview

Documents

Training

Overview

HBV Treatment Management in Sharp Focus

The Aptima® HBV Quant Assay is a molecular HBV treatment management assay with dual-target design. It helps providers guide treatment management for patients with chronic hepatitis B infection who are undergoing antiviral therapy.

Quantitation Across Genotypes

Validated performance across HBV genotypes A – H, with added tolerance to mutations.

Unique Design

Allows laboratorians to deliver trusted results from baseline throughout treatment despite low or high viral loads.

The Latest on Aptima Virology

See More Virology Highlights

The Importance of Universal, Affordable Access to HIV Testing Globally

Promoting universal, affordable access to testing where it is most needed is the mission of Hologic’s Global Access Initiative.

The Decline of HCV Genotyping

A look at the history behind crucial advancements in diagnostics and therapy—and the rationale for streamlining systems that are accessible to patients regardless of genotype.

The Case for NAAT in the HIV Algorithm

Researchers are calling for the CDC to update its guidelines to incorporate HIV testing that gives patients results as soon as possible.

See More Virology Highlights

Quantitate with Confidence

The Aptima HBV Quant assay utilizes a unique dual-target design, providing accuracy in the face of high and low viral loads, genotype variation and mutations, so you can deliver trusted results from baseline measurement throughout treatment.

Sophisticated Design

Unique design. Ultimate confidence.

The Aptima HBV Quant assay is a dual-target molecular assay for HBV treatment management.¹

Targets 2 highly conserved regions in the polymerase and surface genes
Provides added tolerance to mutations in the HBV genome
Ensures accurate quantitation over a wide linear range

High Sensitivity

Track even low-level concentrations of HBV virus across all major HBV genotypes.

The Limit of Detection (LoD) of the Aptima HBV Quant assay is 4.8 IU/mL in plasma samples and 5.9 IU/mL in serum samples, from only 500 μL of reaction volume.*

1) Limit of Detection (LOD) across HBV genotyping using clinical specimens.

2) The LLoQ of the Aptima HBV Quant assay has been thoroughly and rigorously validated across HBV genotypes A-H with thousands of data points, across multiple reagent lots, instruments and operators.¹

*Calculated using the WHO 3^rd International Standard

Claim

Quant

LoD

4.8 IU/mL in plasma
5.9 IU/mL in serum

LLoQ

6 IU/mL in plasma
8 IU/mL in serum

Methodology

RT-TMA

Verified Sample Types*

Serum (SST, serum tubes)
Plasma (EDTA, ACD, PPT)

Your Virology IQ

Test Your Virology Knowledge

Take a quiz on current virology statistics and historic innovations.

Get Started

Question 1 of 2

What are the CDC recommendations for HBV Routine Testing?

Person born in regions of high and intermediate HBV endemicity should be tested with NAAT regardless of vaccination status ×
Person born in regions of high and intermediate HBV endemicity should be tested with HBsAg regardless of vaccination status ✔
Only persons with prior HBV exposure should be tested with HBsAg regardless of vaccination status ×

ANSWER B: Persons born in regions of high and intermediate HBV endemicity (HBsAg prevalence 2%) test for HBsAg, regardless of vaccination status in their country of origin, including immigrants, refugees, asylum seekers, and internationally adopted children. If HBsAg-positive, refer for medical management. If negative, assess for on-going risk for hepatitis B and vaccinate if indicated.

Reference: Adapted from: Centers for Disease Control and Prevention. Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. MMWR 2008; 57 (No. RR-8).

Should pregnant women get tested for HBV?

Yes, test preferably with NAAT during each pregnancy in the last trimester ✔
Yes, test for HBsAg during each pregnancy, preferably in the first trimester ×
No, HBV screening required in pregnant women if person born in low endemicity region ×

ANSWER A: The CDC recommends that all pregnant women test for HBsAg during each pregnancy, preferably in the first trimester. Test at the time of admission for delivery if prenatal HBsAg test result is not available or if mother was at risk for infection during pregnancy. If HBsAg-positive, refer for medical management. To prevent perinatal transmission, infants of HBsAg-positive mothers and unknown HBsAg status mothers should receive vaccination and postexposure immunoprophylaxis in accordance with recommendations and within 12 hours of delivery.

Results

You’re well on your way! Continue reading about the Virology assay suite.
You’ll feel more informed and empowered when speaking with your healthcare provider.

You’re well on your way! Continue reading about the Virology assay suite. You’ll feel more informed and empowered when speaking with your healthcare provider.

Learn More About Virology Take Quiz Again